Inverse relationship between the inflammatory marker Pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 12, 2011, Pages 2785-2791

  Miyamoto, Tetsu ^a,b   Qureshi, Abdul Rashid ^a   Heimbürger, Olof ^a   Bárány, Peter ^a   Carrero, Karin ^a   Sjöberg, Bodil ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a   Carrero, Juan Jesús ^a,c  

^a Intervention and Technology   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; PENTRAXIN 3;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FAT BODY; FAT BODY MASS INDEX; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY, ABDOMINAL; RENAL DIALYSIS; SERUM AMYLOID P-COMPONENT; WAIST CIRCUMFERENCE;

EID: 83155182903     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02320311     Document Type: Article

References (38)

1. de Koning L, Merchant AT, Pogue J, Anand SS: Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective studies. Eur Heart J 28: 850-856, 2007
2. Hotamisligil GS: Inflammation and metabolic disorders. Nature 444: 860-867, 2006
3. Witasp A, Carrero JJ, Heimburger O, Lindholm B, Hammarqvist F, Stenvinkel P, Nordfors L: Increased expression of proinflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. J Intern Med 269: 410-419, 2011
4. Zoccali C, Mallamaci F: Does adipose tissue have a key role in inflammation in CKD? J Intern Med 269: 407-409, 2011
5. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimburger O, Axelsson J, Barany P, Lindholm B, Carrero JJ: Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 25: 562-568, 2010
6. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease-What have we learned in 10 years? Semin Dial 23: 498-509, 2010
7. Carrero JJ, Stenvinkel P: Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: A hypothesis proposal. Clin J Am Soc Nephrol 4[Suppl 1]: S49-S55, 2009
8. Mantovani A, Garlanda C, Doni A, Bottazzi B: Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3. J Clin Immunol 28: 1-13, 2008
9. Norata GD, Garlanda C, Catapano AL: The long pentraxin PTX3: A modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 20: 35-40, 2010
10. Bottazzi B, Doni A, Garlanda C, Mantovani A: An integrated view of humoral innate immunity: Pentraxins as a paradigm. Annu Rev Immunol 28: 157-183, 2010
11. Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, Mantovani A, Invitti C: Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 202: 455-460, 2009
12. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimburger O, Barany P, Axelsson J, Alvestrand A, Stenvinkel P, Lindholm B, Suliman ME: Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2: 889-897, 2007
13. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, Yenicesu M, Tong M, Heimburger O, Barany P, Alvestrand A, Lindholm B, Stenvinkel P: Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 3: 976-985, 2008
14. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ: Soluble TWEAK and PTX3 in nondialysis CKD patients: Impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 6: 785-792, 2011
15. Suliman ME, Qureshi AR, Carrero JJ, Barany P, Yilmaz MI, Snaedal-Jonsdottir S, Alvestrand A, Heimburger O, Lindholm B, Stenvinkel P: The long pentraxin PTX-3 in prevalent hemodialysis patients: Associations with comorbidities and mortality. QJM 101: 397-405, 2008
16. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, Snaedal-Jonsdottir S, Alvestrand A, Heimburger O, Lindholm B, Stenvinkel P: Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 85: 695-701, 2007
17. Snaedal S, Heimburger O, Qureshi AR, Danielsson A, Wikstrom B, Fellstrom B, Fehrman-Ekholm I, Carrero JJ, Alvestrand A, Stenvinkel P, Barany P: Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: Implications for patient survival. Am J Kidney Dis 53: 1024-1033, 2009
18. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
19. Carrero JJ, Witasp A, Stenvinkel P, Qureshi AR, Heimburger O, Barany P, Suliman ME, Anderstam B, Lindholm B, Nordfors L, Schalling M, Axelsson J: Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 25: 901-906, 2010
20. Durnin JV, Womersley J: Body fat assessed from total body density and its estimation from skinfold thickness: Measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32: 77-97, 1974
21. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, Jeejeebhoy KN: What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 11: 8-13, 1987
22. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K: Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 47: 471-477, 2009
23. Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T, Kakitsubata Y, Ishikawa T, Kitamura K, Hatakeyama K, Asada Y, Kodama T: Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity 18: 1871-1874, 2010
24. Bosutti A, Malaponte G, Zanetti M, Castellino P, Heer M, Guarnieri G, Biolo G: Calorie restriction modulates inactivityinduced changes in the inflammatory markers C-reactive protein and pentraxin-3. J Clin Endocrinol Metab 93: 3226-3229, 2008
25. Shim BJ, Jeon HK, Lee SJ, Kim SS, Park MY, Lee DH, Shin WS, Lee JM, Youn HJ, Chung WS, Seung KB: The relationship between serum pentraxin 3 and central obesity in STsegment elevation myocardial infarction patients. Korean Circ J 40: 308-313, 2010
26. Boehme M, Kaehne F, Kuehne A, Bernhardt W, Schroder M, Pommer W, Fischer C, Becker H, Muller C, Schindler R: Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant 22: 2224-2229, 2007
27. Yilmaz MI, Carrero JJ, Martin-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM: Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: Effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 5: 1174-1181, 2010
28. Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P: Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 4: 535-541, 2009
29. Dias AA, Goodman AR, Dos Santos JL, Gomes RN, Altmeyer A, Bozza PT, Horta MF, Vilcek J, Reis LF: TSG-14 transgenic mice have improved survival to endotoxemia and to CLPinduced sepsis. J Leukoc Biol 69: 928-936, 2001
30. Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, Pasqualini F, Latini R, Garlanda C, Mantovani A: Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 117: 1055-1064, 2008
31. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL: Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708, 2009
32. Miyaki A, Maeda S, Otsuki T, Ajisaka R: Plasma pentraxin 3 concentration increases in endurance-trained men. Med Sci Sports Exerc 43: 12-17, 2011
33. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL: Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28: 925-931, 2008
34. Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P: The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 19: 37-42, 2010
35. Park SH, Carrero JJ, Lindholm B, Stenvinkel P: Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: Two sides of the same coin. Clin Nephrol 72: 87-96, 2009
36. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761, 2004
37. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T: Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70: 1717-1724, 2006
38. Barazzoni R, Bernardi A, Biasia F, Semolic A, Bosutti A, Mucci M, Dore F, Zanetti M, Guarnieri G: Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease-Impact on plasma adiponectin concentration. Am J Physiol Regul Integr Comp Physiol 293: R47-R54, 2007